San Diego—In patients with chronic myeloid leukemia (CML), longer treatment duration is associated with an increase in the odds ratio for preserving a major molecular response (MMR) six months after discontinuing tyrosine kinase inhibitor (TKI) therapy, according to recent data from a large study. In contrast, the depth of molecular response was not a predictor of molecular relapse-free survival (MRFS).
François-Xavier Mahon, MD, PhD
In EURO-SKI (European Stop Tyrosine Kinase